Publications

Found 2 results
Filters: Author is Z. Hussain  [Clear All Filters]
2013
Z. Hussain, Khan, M. I., Shahid, M., and Almajhdi, F. N., S-adenosylmethionine, a methyl donor, up regulates tissue inhibitor of metalloproteinase-2 in colorectal cancer, vol. 12, pp. 1106-1118, 2013.
Ateeq B, Unterberger A, Szyf M and Rabbani SA (2008). Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10: 266-278. PMid:18320071 PMCid:2259455   Baylin SB, Esteller M, Rountree MR, Bachman KE, et al. (2001). Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10: 687-692. http://dx.doi.org/10.1093/hmg/10.7.687 PMid:11257100   Bird NC, Mangnall D and Majeed AW (2006). Biology of colorectal liver metastases: A review. J. Surg. Oncol. 94: 68-80. http://dx.doi.org/10.1002/jso.20558 PMid:16788948   Brown R and Strathdee G (2002). Epigenomics and epigenetic therapy of cancer. Trends Mol. Med. 8: S43-S48. http://dx.doi.org/10.1016/S1471-4914(02)02314-6   Carmeliet P and Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257. http://dx.doi.org/10.1038/35025220 PMid:11001068   Chiang PK, Gordon RK, Tal J, Zeng GC, et al. (1996). S-Adenosylmethionine and methylation. FASEB J. 10: 471-480. PMid:8647346   DeClerck YA, Perez N, Shimada H, Boone TC, et al. (1992). Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52: 701-708. PMid:1732058   Detich N, Hamm S, Just G, Knox JD, et al. (2003). The methyl donor S-Adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-Adenosylmethionine. J. Biol. Chem. 278: 20812-20820. http://dx.doi.org/10.1074/jbc.M211813200 PMid:12676953   Ehrlich M (2002). DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413. http://dx.doi.org/10.1038/sj.onc.1205651 PMid:12154403   Esteller M (2005). DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 17: 55-60. http://dx.doi.org/10.1097/01.cco.0000147383.04709.10 PMid:15608514   Esteller M, Corn PG, Baylin SB and Herman JG (2001). A gene hypermethylation profile of human cancer. Cancer Res. 61: 3225-3229. PMid:11309270   Futschik M, Jeffs A, Pattison S, Kasabov N, et al. (2002). Gene expression profiling of metastatic and nonmetastatic colorectal cancer cell lines. Genome Lett. 1: 26-34. http://dx.doi.org/10.1166/gl.2002.005   Galm O, Suzuki H, Akiyama Y, Esteller M, et al. (2005). Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies. Oncogene 24: 4799-4805. http://dx.doi.org/10.1038/sj.onc.1208599 PMid:15870703   Gokaslan ZL, Chintala SK, York JE, Boyapati V, et al. (1998). Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin. Exp. Metastasis 16: 721-728. http://dx.doi.org/10.1023/A:1006580728338 PMid:10211985   Gomez DE, Alonso DF, Yoshiji H and Thorgeirsson UP (1997). Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74: 111-122. PMid:9352216   Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, et al. (2001). Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res. 61: 3450-3457. PMid:11309307   Imren S, Kohn DB, Shimada H, Blavier L, et al. (1996). Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 56: 2891-2895. PMid:8674034   Ivanova T, Vinokurova S, Petrenko A, Eshilev E, et al. (2004). Frequent hypermethylation of 5' flanking region of TIMP-2 gene in cervical cancer. Int. J. Cancer 108: 882-886. http://dx.doi.org/10.1002/ijc.11652 PMid:14712492   Jemal A, Siegel R, Ward E, Hao Y, et al. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58: 71-96. http://dx.doi.org/10.3322/CA.2007.0010 PMid:18287387   Kerbel RS (2008). Tumor angiogenesis. N. Engl. J. Med. 358: 2039-2049. http://dx.doi.org/10.1056/NEJMra0706596 PMid:18463380   Kretzschmar M (2000). Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res. 2: 107-115. http://dx.doi.org/10.1186/bcr42 PMid:11250700 PMCid:139432   Liotta LA, Tryggvason K, Garbisa S, Hart I, et al. (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68. http://dx.doi.org/10.1038/284067a0 PMid:6243750   Liotta LA, Steeg PS and Stetler-Stevenson WG (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336. http://dx.doi.org/10.1016/0092-8674(91)90642-C   Mazar AP, Henkin J and Goldfarb RH (1999). The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 3: 15-32. http://dx.doi.org/10.1023/A:1009095825561 PMid:14517441   McMillan DC and McArdle CS (2007). Epidemiology of colorectal liver metastases. Surg. Oncol. 16: 3-5. http://dx.doi.org/10.1016/j.suronc.2007.04.008 PMid:17493802   Mollabashy A and Scarborough M (2000). The mechanism of metastasis. Orthop. Clin. North Am. 31: 529-535. http://dx.doi.org/10.1016/S0030-5898(05)70172-3   Pakneshan P, Szyf M, Farias-Eisner R and Rabbani SA (2004). Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J. Biol. Chem. 279: 31735-31744. http://dx.doi.org/10.1074/jbc.M401669200 PMid:15150277   Parkin DM, Bray F, Ferlay J and Pisani P (2001). Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94: 153-156. http://dx.doi.org/10.1002/ijc.1440 PMid:11668491   Pulukuri SM, Patibandla S, Patel J, Estes N, et al. (2007). Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 26: 5229-5237. http://dx.doi.org/10.1038/sj.onc.1210329 PMid:17325663 PMCid:2084378   Rao JS (2003). Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 3: 489-501. http://dx.doi.org/10.1038/nrc1121 PMid:12835669   Razin A and Riggs AD (1980). DNA methylation and gene function. Science 210: 604-610. http://dx.doi.org/10.1126/science.6254144 PMid:6254144   Rothbarth J and van de Velde CJ (2005). Treatment of liver metastases of colorectal cancer. Ann. Oncol. 16: 144-149.   Shukeir N, Pakneshan P, Chen G, Szyf M, et al. (2006). Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66: 9202-9210. http://dx.doi.org/10.1158/0008-5472.CAN-06-1954 PMid:16982764   Stetler-Stevenson WG, Aznavoorian S and Liotta LA (1993). Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9: 541-573. http://dx.doi.org/10.1146/annurev.cb.09.110193.002545 PMid:8280471   Suzuki H, Gabrielson E, Chen W, Anbazhagan R, et al. (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31: 141-149. http://dx.doi.org/10.1038/ng892 PMid:11992124   Valente P, Fassina G, Melchiori A, Masiello L, et al. (1998). TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer 75: 246-253. http://dx.doi.org/10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B   Yamamoto M, Mohanam S, Sawaya R, Fuller GN, et al. (1996). Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res. 56: 384-392. PMid:8542596   Yi JM, Dhir M, Guzzetta AA, Iacobuzio-Donahue CA, et al. (2012). DNA methylation biomarker candidates for early detection of colon cancer. Tumour. Biol. 33: 363-372. http://dx.doi.org/10.1007/s13277-011-0302-2 PMid:22238052 PMCid:3593674   Yin JJ, Selander K, Chirgwin JM, Dallas M, et al. (1999). TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103: 197-206. http://dx.doi.org/10.1172/JCI3523 PMid:9916131 PMCid:407876   Yoon SO, Kim MM and Chung AS (2001). Inhibitory effect of selenite on invasion of HT1080 tumor cells. J. Biol. Chem. 276: 20085-20092. http://dx.doi.org/10.1074/jbc.M101143200 PMid:11274215
2012
A. Al-Qahtani, Alarifi, S., Al-Okail, M., Hussain, Z., Abdo, A., Sanai, F., Al-Anazi, M., Khalaf, N., Al-Humaidan, H., Al-Ahdal, M., and Almajhdi, F. N., RANTES gene polymorphisms (-403G>A and -28C>G) associated with hepatitis B virus infection in a Saudi population, vol. 11, pp. 855-862, 2012.
Ahn SH, Kim dY, Chang HY, Hong SP, et al. (2006). Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. J. Med. Virol. 78: 1564-1571. http://dx.doi.org/10.1002/jmv.20739 PMid:17063508 Ajuebor MN, Wondimu Z, Hogaboam CM, Le T, et al. (2007). CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am. J. Pathol. 170: 1975-1988. http://dx.doi.org/10.2353/ajpath.2007.060690 PMid:17525265    PMCid:1899451 An P, Nelson GW, Wang L, Donfield S, et al. (2002). Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc. Natl. Acad. Sci. U. S. A. 99: 10002-10007. http://dx.doi.org/10.1073/pnas.142313799 PMid:12114533    PMCid:126614 Bowen DG and Walker CM (2005). Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J. Exp. Med. 201: 1709-1714. http://dx.doi.org/10.1084/jem.20050808 PMid:15939787    PMCid:2213256 Bracci PM, Skibola CF, Conde L, Halperin E, et al. (2010). Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk. Lymphoma 51: 497-506. http://dx.doi.org/10.3109/10428190903518337 Centi S, Negrisolo S, Stefanic A, Benetti E, et al. (2010). Upper urinary tract infections are associated with RANTES promoter polymorphism. J. Pediatr. 157: 1038-1040. http://dx.doi.org/10.1016/j.jpeds.2010.08.006 PMid:20869067 Cheong JY, Cho SW, Choi JY, Lee JA, et al. (2007). RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection: results from a large scale single ethnic population. J. Korean Med. Sci. 22: 529-535. http://dx.doi.org/10.3346/jkms.2007.22.3.529 PMid:17596666    PMCid:2693650 Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, et al. (1995). Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811-1815. http://dx.doi.org/10.1126/science.270.5243.1811 PMid:8525373 Duan ZP, Zhao XY, Huang DZ, He LX, et al. (2005). RANTES gene single nucleotide polymorphisms and expression in patients with chronic hepatitis B virus infection. Chin. Med. J. 118: 909-914. Durantel D and Zoulim F (2009). Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus. Hepatology 50: 1692-1695. http://dx.doi.org/10.1002/hep.23361 PMid:19937686 Gonzalez E, Rovin BH, Sen L, Cooke G, et al. (2002). HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc. Natl. Acad. Sci. U. S. A. 99: 13795-13800. http://dx.doi.org/10.1073/pnas.202357499 PMid:12374865    PMCid:129777 Grakoui A, Shoukry NH, Woollard DJ, Han JH, et al. (2003). HCV persistence and immune evasion in the absence of memory T cell help. Science 302: 659-662. http://dx.doi.org/10.1126/science.1088774 PMid:14576438 Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, et al. (2003). Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38: 1468-1476. PMid:14647058 Hizawa N, Yamaguchi E, Konno S, Tanino Y, et al. (2002). A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. Am. J. Respir. Crit. Care Med. 166: 686-690. http://dx.doi.org/10.1164/rccm.200202-090OC PMid:12204866 Lee WM (1997). Hepatitis B virus infection. N. Engl. J. Med. 337: 1733-1745. http://dx.doi.org/10.1056/NEJM199712113372406 PMid:9392700 Liu H, Chao D, Nakayama EE, Taguchi H, et al. (1999). Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. U. S. A. 96: 4581-4585. http://dx.doi.org/10.1073/pnas.96.8.4581 Ma K, Xu W, Shao X, Yanyue, et al. (2007). Coimmunization with RANTES plasmid polarized Th1 immune response against hepatitis B virus envelope via recruitment of dendritic cells. Antiviral Res. 76: 140-149. http://dx.doi.org/10.1016/j.antiviral.2007.06.012 PMid:17655942 Nam SH, Park JH, Kang JH, Kang SY, et al. (2006). Modulation of immune response induced by co-administration of DNA vaccine encoding HBV surface antigen and HCV envelope antigen in BALB/c mice. Arch. Pharm. Res. 29: 1042-1048. http://dx.doi.org/10.1007/BF02969289 PMid:17146974 Nelson PJ, Ortiz BD, Pattison JM and Krensky AM (1996). Identification of a novel regulatory region critical for expression of the RANTES chemokine in activated T lymphocytes. J. Immunol. 157: 1139-1148. PMid:8757619 Ness TL, Carpenter KJ, Ewing JL, Gerard CJ, et al. (2004). CCR1 and CC chemokine ligand 5 interactions exacerbate innate immune responses during sepsis. J. Immunol. 173: 6938-6948. PMid:15557190 Nickel RG, Casolaro V, Wahn U, Beyer K, et al. (2000). Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J. Immunol. 164: 1612-1616. PMid:10640782 Park BL, Kim YJ, Cheong HS, Kim LH, et al. (2006). Association of common promoter polymorphisms of MCP1 with hepatitis B virus clearance. Exp. Mol. Med. 38: 694-702. PMid:17202846 Rehermann B, Lau D, Hoofnagle JH and Chisari FV (1996). Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin. Invest. 97: 1655-1665. http://dx.doi.org/10.1172/JCI118592 PMid:8601631    PMCid:507230 Thio CL, Astemborski J, Thomas R, Mosbruger T, et al. (2008). Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. J. Immunol. 181: 7944-7947. PMid:19017985    PMCid:2650505 Watson RW (2002). The rising incidence of hepatocellular carcinoma. N. Engl. J. Med. 341: 451-452. Zhang YG, Huang J, Zhang J, Li XB, et al. (2010). RANTES gene polymorphisms and asthma risk: A meta-analysis. Arch. Med. Res. 41: 50-58. http://dx.doi.org/10.1016/j.arcmed.2010.01.002 PMid:20430255 Zhao XY, Lee SS, Wong KH, Chan KC, et al. (2004). Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. Eur. J. Immunogenet. 31: 179-183. http://dx.doi.org/10.1111/j.1365-2370.2004.00466.x PMid:15265023 Zhernakova A, Alizadeh BZ, Eerligh P, Hanifi-Moghaddam P, et al. (2006). Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes. Genes Immun. 7: 544-549. http://dx.doi.org/10.1038/sj.gene.6364326 PMid:16855620